Editor’s Note: Every week, you watch stocks from industries across the board pop (or drop), but you may be wondering if it’s time to buy in. That’s what today’s Stock Power Daily is all about. We’ll show you some of the week’s biggest movers, and then run them through Adam O’Dell’s proprietary Green Zone Power Ratings to see how they stack up.
Greenfire Resources Ltd. (NYSE: GFR): The “High-Risk” stock sank 10% on Friday after entering the public market last week via a SPAC deal with M3-Brigade Acquisition III Corp.
Structure Therapeutics Inc. (Nasdaq: GPCR): Investors are betting big on this biopharmaceutical company that’s developed another breakthrough fat-loss drug. The stock is up almost 50% this week, but it’s still “High-Risk” in Green Zone Power Ratings.
TAL Education Group (NYSE: TAL): This Chinese education provider is up 28% this week after giving positive future guidance. We’ll see if that improves its “Neutral” stock rating.
Corcept Therapeutics Inc. (Nasdaq: CORT): The “Strong Bullish” biopharma sank almost 20% on Friday. Maybe this is a buying opportunity?
C3.ai Inc. (NYSE: AI): Chad showed you yesterday that this is still a “High-Risk” artificial intelligence stock in our system, but that didn’t stop investors from pushing it 6.6% higher over the week.
Speaking of AI, we have a special guest article from our colleagues over at TradeSmith to share with you. You can go here to read about how to invest “in” AI and “with” AI and win both ways. Once you’re done reading, make sure to sign up for Adam and TradeSmith CEO Keith Kaplan’s special presentation that’s happening at 8 p.m. Eastern time, this coming Tuesday.
Privacy Policy The Money & Markets, P.O. Box 8378, Delray Beach, FL 33482.
To ensure that you receive future issues of Money & Markets, please add info@mb.moneyandmarkets.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance.
The mailbox associated with this email address is not monitored, so please do not reply. Your feedback is very important to us so if you would like to contact us with a question or comment, please click here: https://moneyandmarkets.com/contact-us/
Legal Notice: This work is based on what we've learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It's your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Certain investments carry large potential rewards but also large potential risk. Don't trade in these markets with money you can't afford to lose. Money & Markets permits editors of a publication to recommend a security to subscribers that they own themselves. However, in no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. Any exit after a buy recommendation is made and prior to issuing a sell notification is forbidden. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication.
(c) 2023 Money & Markets, LLC. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of Money & Markets. P.O. Box 8378, Delray Beach, FL 33482. (TEL: 800-684-8471)
Post a Comment
Post a Comment